BRIEF—CBT and Strata partner on trial enrollment

Precision medicine specialist Strata Oncology has partnered with the Sino-American drugmaker CBT Pharmaceuticals to drive patient enrollment in CBT’s ongoing Phase I/II trial of CBT-101.

The trial is evaluating the candidate in people with c-Met dysregulated malignancies including non-small cell lung cancer.

Strata will exclusively refer Met-amplified, Met-mutation and Met-fusion advanced cancer patients identified through the Strata Trial for enrollment consideration into CBT’s clinical development program for CBT-101.

The Strata Trial is a genomic screening protocol provided as part of routine care to around 100,000 people with cancer annually.